loading
Artelo Biosciences Inc stock is traded at $2.70, with a volume of 12,300. It is down -1.46% in the last 24 hours and down -28.00% over the past month. Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
See More
Previous Close:
$2.74
Open:
$2.75
24h Volume:
12,300
Relative Volume:
0.32
Market Cap:
$1.48M
Revenue:
Net Income/Loss:
$-13.47M
P/E Ratio:
-0.0694
EPS:
-38.9215
Net Cash Flow:
$-8.38M
1W Performance:
-17.18%
1M Performance:
-28.00%
6M Performance:
-93.83%
1Y Performance:
-97.51%
1-Day Range:
Value
$2.70
$2.7594
1-Week Range:
Value
$2.70
$3.25
52-Week Range:
Value
$2.70
$179.19

Artelo Biosciences Inc Stock (ARTL) Company Profile

Name
Name
Artelo Biosciences Inc
Name
Phone
858-925-7049
Name
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Name
Employee
7
Name
Twitter
@ArteloBio
Name
Next Earnings Date
2026-11-11
Name
Latest SEC Filings
Name
ARTL's Discussions on Twitter

Compare ARTL vs VRTX, MRNA, REGN, ARGX, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ARTL icon
ARTL
Artelo Biosciences Inc
2.70 1.48M 0 -13.47M -8.38M -38.92
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-08-25 Upgrade D. Boral Capital Hold → Buy
Feb-12-21 Initiated Ladenburg Thalmann Buy

Artelo Biosciences Inc Stock (ARTL) Latest News

pulisher
Sep 24, 2026

Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket - Benzinga

Sep 24, 2026
pulisher
Sep 23, 2026

Let's take a look at the stocks that are in motion in today's session. - ChartMill

Sep 23, 2026
pulisher
Sep 11, 2026

Artelo Biosciences at H.C. Wainwright: early data, tight cash By Investing.com - Investing.com South Africa

Sep 11, 2026
pulisher
Sep 11, 2026

Artelo Biosciences at H.C. Wainwright: early data, tight cash By Investing.com - Investing.com Canada

Sep 11, 2026
pulisher
Sep 11, 2026

Artelo Biosciences at H.C. Wainwright: early data, tight cash By Investing.com - Investing.com UK

Sep 11, 2026
pulisher
Sep 08, 2026

Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference - ca.finance.yahoo.com

Sep 08, 2026
pulisher
Sep 05, 2026

Artelo Biosciences Stock Price Forecast. Should You Buy ARTL? - StockInvest.us

Sep 05, 2026
pulisher
Sep 03, 2026

Artelo Biosciences Inc. Warrant (ARTLW) Peer Comparison – Compare with Others - Value Research

Sep 03, 2026
pulisher
Sep 02, 2026

Artelo Biosciences Inc. Warrant (ARTLW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research

Sep 02, 2026
pulisher
Sep 02, 2026

Artelo Biosciences Inc. Warrant (ARTLW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Sep 02, 2026
pulisher
Aug 31, 2026

Artelo Biosciences Inc (NASDAQ: ARTL) Share Price, ARTL Stock News, ARTL Share Price & Updates - kalkine.ca

Aug 31, 2026
pulisher
Aug 28, 2026

Artelo Biosciences Inc. (ARTL) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com

Aug 28, 2026
pulisher
Aug 27, 2026

Artelo Biosciences To Carry Out 1-for-9 Reverse Stock Split On August 31st, 2026 - Moomoo

Aug 27, 2026
pulisher
Aug 27, 2026

Artelo Biosciences Inc. (ARTL) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com

Aug 27, 2026
pulisher
Aug 27, 2026

Artelo Biosciences announces 1-for-9 reverse stock split - Investing.com India

Aug 27, 2026
pulisher
Aug 27, 2026

Artelo Biosciences (Nasdaq: ARTL) to trade post-split Aug 31 - Stock Titan

Aug 27, 2026
pulisher
Aug 27, 2026

Artelo Biosciences announces 1-for-9 reverse stock split - Investing.com

Aug 27, 2026
pulisher
Aug 27, 2026

Artelo Biosciences announces 1-for-9 reverse stock split By Investing.com - Investing.com Canada

Aug 27, 2026
pulisher
Aug 27, 2026

Artelo Biosciences announces 1-for-9 reverse stock split By Investing.com - Investing.com UK

Aug 27, 2026
pulisher
Aug 27, 2026

Artelo Biosciences Announces Reverse Stock Split - Barchart.com

Aug 27, 2026
pulisher
Aug 27, 2026

Artelo Biosciences Announces Reverse Stock Split - finance.yahoo.com

Aug 27, 2026
pulisher
Aug 27, 2026

Artelo Biosciences will combine every 9 shares into 1 starting Aug. 31 - Stock Titan

Aug 27, 2026
pulisher
Aug 22, 2026

Artelo (ARTL) Technicals: Declines 2.86% to $0.69 at the Close; Range View - vinanet.vn

Aug 22, 2026
pulisher
Aug 20, 2026

Armistice Capital Exits Artelo Biosciences (ARTL) Position in Co - GuruFocus

Aug 20, 2026
pulisher
Aug 20, 2026

Artelo Biosciences wins Japan patent allowance for ART27.13 commercial formulation - Bitget

Aug 20, 2026
pulisher
Aug 20, 2026

Artelo Biosciences (ARTL) Secures Japanese Patent for ART27.13, Extending IP Protection to 2041 - GuruFocus

Aug 20, 2026
pulisher
Aug 20, 2026

Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 - The Manila Times

Aug 20, 2026
pulisher
Aug 20, 2026

Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 - Yahoo Finance

Aug 20, 2026
pulisher
Aug 18, 2026

Artelo (ARTL) Results at a Glance: The Latest Report Adds New Financial Reference Points at the Close; Share Response: Shares Move 1.25% Up in the Latest ReadingEarnings Preview - vinanet.vn

Aug 18, 2026
pulisher
Aug 17, 2026

Artelo Biosciences (ARTL) Q2 2026 Earnings: Clinical-Stage Firm Posts $0.89 Per Share Loss as Shares Fall 8.76%Geographic Revenue Trends - dars.gov.et

Aug 17, 2026
pulisher
Aug 17, 2026

Artelo Biosciences (ARTL) Q2 2026 Earnings: Clinical-Stage Firm Posts $0.89 Per Share Loss as Shares Fall 8.76%Earnings Analysis - vinanet.vn

Aug 17, 2026
pulisher
Aug 17, 2026

Artelo Biosciences (ARTL) Secures Patent Allowance for ART27.13 Commercial Formulation - GuruFocus

Aug 17, 2026
pulisher
Aug 17, 2026

Artelo Biosciences Receives a Notice of Allowance from the - GlobeNewswire

Aug 17, 2026
pulisher
Aug 17, 2026

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies - Yahoo Finance

Aug 17, 2026
pulisher
Aug 15, 2026

ARTL Q2 2026 Earnings: Reported EPS of -$0.89 Reflects Continued Development FocusROIC Trend Report - vinanet.vn

Aug 15, 2026
pulisher
Aug 15, 2026

Artelo Biosciences reports positive ART27.13 results in neuropathic pain model - scanx.trade

Aug 15, 2026
pulisher
Aug 15, 2026

Artelo Biosciences data supports ART26.12 for spinal cord injury pain - scanx.trade

Aug 15, 2026
pulisher
Aug 14, 2026

ARTL Q2 2026 Earnings: Reported Loss of -$0.89 Per Share Highlights Clinical-Stage InvestmentGuidance vs Actual - vinanet.vn

Aug 14, 2026
pulisher
Aug 14, 2026

Artelo Biosciences (ARTL) major holder reports 0% ownership in new 13G/A - Stock Titan

Aug 14, 2026
pulisher
Aug 13, 2026

Artelo Biosciences Releases Q2 2026 Financial Results - news.alphastreet.com

Aug 13, 2026
pulisher
Aug 13, 2026

Artelo Biosciences Releases Q2 2026 Financial Results - AlphaStreet

Aug 13, 2026
pulisher
Aug 13, 2026

Artelo Biosciences Q2 Results: EPS loss narrows 95% YoY to $(0.89) - scanx.trade

Aug 13, 2026
pulisher
Aug 13, 2026

Artelo Biosciences (ARTL) investors disclose 4.8% stake via Intracoastal warrant - Stock Titan

Aug 13, 2026
pulisher
Aug 13, 2026

Artelo Biosciences Q2 Net Income USD -2.4 Mil - Moomoo

Aug 13, 2026
pulisher
Aug 13, 2026

Artelo Plans Q4 Trial After ART26.12 Matches Naproxen for Pain - Stock Titan

Aug 13, 2026
pulisher
Aug 12, 2026

Artelo Biosciences (ARTL) trims liabilities, boosts cash amid $5.4M H1 loss - Stock Titan

Aug 12, 2026
pulisher
Aug 11, 2026

Artelo Biosciences (ARTL) Advances 6.34% to $0.75 as Micro-Cap Biotech Tests Key ResistanceDebt Free Companies - vinanet.vn

Aug 11, 2026
pulisher
Aug 10, 2026

Artelo Biosciences doses first patient in Phase 2 glaucoma trial of ART27.13 - Bitget

Aug 10, 2026
pulisher
Aug 10, 2026

Artelo Biosciences doses first patient in Phase 2 glaucoma trial of ART27.13 - Bitget

Aug 10, 2026
pulisher
Aug 10, 2026

Artelo Biosciences doses first patient in Phase 2 glaucoma trial of ART27.13 - Bitget

Aug 10, 2026

Artelo Biosciences Inc Stock (ARTL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$6.58
price down icon 4.22%
$9.94
price down icon 3.21%
$5.53
price down icon 3.66%
$11.27
price down icon 6.16%
$18.60
price down icon 1.74%
WVE WVE
$3.13
price down icon 1.88%
Cap:     |  Volume (24h):